Earnings summaries and quarterly performance for INSMED.
Executive leadership at INSMED.
Board of directors at INSMED.
Research analysts who have asked questions during INSMED earnings calls.
Jason Zemansky
Bank of America
8 questions for INSM
Also covers: ABOS, BBIO, CYTK +5 more
JF
Jessica Fye
JPMorgan Chase & Co.
8 questions for INSM
Also covers: ALKS, ALNY, AMRN +23 more
JS
Joseph Schwartz
Oppenheimer
8 questions for INSM
Also covers: ASND, AUPH, BMRN +14 more
RB
Ritu Baral
TD Cowen
8 questions for INSM
Also covers: ACAD, ALNY, ATAI +11 more
Vamil Divan
Guggenheim Securities
8 questions for INSM
Also covers: ABBV, ABSI, ANIP +7 more
AN
Andrea Newkirk
Goldman Sachs
6 questions for INSM
Also covers: ABCL, ALKS, ARWR +9 more
Graig Suvannavejh
Mizuho Securities
6 questions for INSM
Also covers: ADAP, ADVM, ALEC +11 more
Jennifer Kim
Cantor Fitzgerald
6 questions for INSM
Also covers: BLTE, CPRX, EYPT +1 more
Liisa Bayko
Evercore ISI
5 questions for INSM
Also covers: ALT, BCRX, IPHA +7 more
MS
Maxwell Skor
H.C. Wainwright & Co.
5 questions for INSM
Also covers: ASND, AVIR, CRNX +4 more
NG
Nicole Germino
Truist Securities
5 questions for INSM
Also covers: CRIS, GILD, SGMO +1 more
SW
Stephen Willey
Stifel Financial Corp.
4 questions for INSM
Also covers: ABCL, CELC, CGEN +10 more
Andy Chen
Wolfe Research, LLC
3 questions for INSM
Also covers: ARGX, CRNX, IMVT +7 more
JH
Jeff Hung
Morgan Stanley
3 questions for INSM
Also covers: ACAD, ALEC, BHVN +10 more
Leonid Timashev
RBC Capital Markets
3 questions for INSM
Also covers: ADCT, ALKS, AXSM +8 more
AT
Andrea Tan
Goldman Sachs
2 questions for INSM
Also covers: ABCL, ARWR, DAWN +3 more
AV
Ash Verma
UBS
2 questions for INSM
Also covers: ALVO, AVDL, EXEL +5 more
Ben Burnett
Stifel
2 questions for INSM
Also covers: ALKS, ALLO, FATE +1 more
CH
Chong Hun
UBS
2 questions for INSM
Clara Dong
Jefferies
2 questions for INSM
Also covers: AUTL, HRTX, LEGN +1 more
Gavin Clark-Gartner
Evercore ISI
2 questions for INSM
Also covers: ACRS, ARGX, ASND +11 more
LT
Lena Times
RBC Capital Markets
2 questions for INSM
LW
Leon Wang
Barclays
2 questions for INSM
Matthew Phipps
William Blair
2 questions for INSM
Also covers: ABBV, AGEN, AMGN +8 more
OB
Olivia Brayer
Cantor
2 questions for INSM
Also covers: AMGN, AUPH, BMRN +8 more
SL
Sam Long
Mizuho
2 questions for INSM
SW
Stephen Willey
Stifel
2 questions for INSM
Also covers: ABCL, ABEO, CGEN +7 more
AC
Andy Chan
Wolfe Research
1 question for INSM
Also covers: IMVT
AC
Andy Chin
Wolfe Research
1 question for INSM
AH
Andy Hsieh
William Blair & Company
1 question for INSM
Also covers: ALT, BYSI, CRDF +8 more
Brandon Frith
Wolfe Research, LLC
1 question for INSM
Also covers: NTLA, ROIV
Kelly Shi
Jefferies
1 question for INSM
Also covers: ADCT, AGEN, ALDX +17 more
TH
Trung Ho
UBS
1 question for INSM
TH
Trung Huynh
UBS Group AG
1 question for INSM
Also covers: ABBV, ABOS, AMGN +5 more
Recent press releases and 8-K filings for INSM.
INSMED Announces Discontinuation of Brensocatib CRSsNP Program and Acquisition of INS1148
INSM
M&A
New Projects/Investments
- On December 17, 2025, Insmed Incorporated announced that its Phase 2b BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps (CRSsNP) did not meet its primary or secondary efficacy endpoints.
- Following these results, Insmed has discontinued its development program of brensocatib in CRSsNP.
- Concurrently, Insmed announced the acquisition of INS1148, a Phase 2 ready investigational monoclonal antibody with potential for respiratory and immunological and inflammatory indications.
- Insmed plans to advance INS1148 into Phase 2 development, initially targeting interstitial lung disease and moderate-to-severe asthma.
7 days ago
Insmed Discontinues Brensocatib CRSsNP Program and Acquires INS1148
INSM
New Projects/Investments
M&A
- Insmed announced that the Phase 2b BiRCh study of brensocatib in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) did not meet its primary or secondary efficacy endpoints.
- As a result, Insmed has discontinued its development program of brensocatib in CRSsNP effective immediately.
- The company also announced the acquisition of INS1148, an investigational monoclonal antibody with the potential to be a first-in-class therapy for respiratory and immunological and inflammatory diseases.
- Insmed plans to advance Phase 2 development programs for INS1148 initially in interstitial lung disease and moderate-to-severe asthma.
7 days ago
Insmed Provides Update on Brenzavvy Launch, Pipeline Progress, and Upcoming Data Readouts
INSM
Product Launch
New Projects/Investments
Guidance Update
- Insmed launched Brenzavvy in August, reporting 2,500 new patient starts and 1,700 prescribers in the first six weeks, with an estimated global peak sales potential of $5 billion for bronchiectasis. The drug also received EU approval.
- Upcoming data readouts include Arikayce label expansion data in H1 2026, potentially increasing the addressable patient population tenfold to 250,000.
- The Birch trial for Brensocatib in chronic rhinosinusitis (CRS) is expected to read out by early January, with potential to be a significant market opportunity.
- Insmed is advancing its pipeline with TPIP (Treprostinil palmitil inhalation powder) in Phase 3 for PH-ILD, IPF, and PPF, and early-stage programs like DMD, ALS, and next-gen DPP1s moving into the clinic.
- The company anticipates a ramp-up in OpEx over time due to multiple forthcoming Phase 3 trials.
Dec 2, 2025, 4:15 PM
Insmed CFO Discusses 2026 Outlook, Product Launches, and Pipeline Progress
INSM
Product Launch
Guidance Update
New Projects/Investments
- Insmed anticipates a "tremendous 2026" following a strong 2025, driven by several key data readouts and program advancements.
- The company expects a potential expansion of its Arikayce addressable patient population from 25,000 to 250,000 patients in its three territories, pending Encore data readout in the first half of next year.
- Brenzavvy, launched in August, recorded over 2,500 new patient starts and 1,700 prescribers in its initial six weeks of sales, with global peak sales for bronchiectasis estimated at $5 billion.
- Data for Brensocatib's Birch trial (chronic rhinosinusitis) is expected by early January, with the potential to be as large or larger than the bronchiectasis opportunity, targeting a U.S. patient population of 30 million.
Dec 2, 2025, 4:15 PM
Insmed CFO Discusses 2026 Outlook, Brenzavvy Launch, and Pipeline Progress
INSM
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Insmed's CFO, Sara Bonstein, highlighted the company's strong performance in 2025 and anticipates a significant 2026 driven by product launches and clinical data readouts.
- Brenzavvy, launched in August 2025, recorded over 2,500 new patient starts and 1,700 prescribers in its initial six weeks, with a global peak sales potential of $5 billion for bronchiectasis. The company expects to launch Brenzavvy in Europe in the first half of 2026 and Japan in the second half.
- Key clinical data readouts expected in 2026 include Arikayce's Encore data in the first half, potentially expanding its addressable patient population from 25,000 to 250,000. The Birch trial data for Brensocatib in chronic rhinosinusitis (CRS) is expected by early January, with the potential to be as large as the bronchiectasis opportunity.
- Insmed is advancing TPIP into Phase 3 for four indications, including PH-ILD, IPF, and PPF, with initial PAH open-label extension data potentially available in the second half of 2026.
- The company anticipates a substantial ramp in operating expenses due to multiple ongoing and forthcoming Phase 3 programs across its pipeline, including CRS, HS, and TPIP indications.
Dec 2, 2025, 4:15 PM
Insmed Announces European Commission Approval of BRINSUPRI for Non-Cystic Fibrosis Bronchiectasis
INSM
Product Launch
New Projects/Investments
- Insmed Incorporated (INSM) announced on November 18, 2025, that the European Commission (EC) has approved BRINSUPRI (brensocatib 25 mg tablets) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months.
- This approval establishes BRINSUPRI as the first and only approved treatment for NCFB in the European Union (EU), a condition affecting an estimated 600,000 people in the region.
- The approval is based on data from the Phase 3 ASPEN study, which demonstrated a 19.4% reduction in the annual rate of exacerbations for patients receiving BRINSUPRI 25 mg compared to placebo.
- Insmed anticipates securing access for eligible patients across the EU starting in early 2026.
Nov 18, 2025, 9:15 PM
Insmed's BRINSUPRI Receives European Commission Approval for NCFB
INSM
Product Launch
New Projects/Investments
- The European Commission has approved BRINSUPRI (brensocatib 25 mg tablets) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months.
- This approval makes BRINSUPRI the first and only approved treatment indicated for NCFB in the European Union (EU), following an accelerated assessment by the EMA.
- Clinical data from the Phase 3 ASPEN study showed that BRINSUPRI 25 mg resulted in a 19.4% reduction in the annual rate of exacerbations compared to placebo and significantly prolonged the time to first exacerbation.
- Insmed will engage with authorities across the EU to secure patient access to BRINSUPRI starting in early 2026.
Nov 18, 2025, 4:00 PM
Insmed Provides Update on Product Launches and Pipeline Developments
INSM
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Insmed reported $28 million in revenue for Brinsupri (brensocatib) in its initial partial quarter launch for bronchiectasis, with CEO Will Lewis stating the medicine could achieve $5 billion in peak sales in this indication.
- Key data for brensocatib in Chronic Rhinosinusitis (CRS) is expected by the end of 2025, with public release in early January 2026, targeting a potential market of over 30 million patients in the U.S..
- The ENCORE trial readout for ARIKAYCE is anticipated in the first half of 2026, potentially expanding its addressable market from 30,000 to over 250,000 patients.
- Insmed plans to initiate Phase 3 trials for TPIP (Treprostinil Palmitil Inhalation Powder) in PAH, PH-ILD, IPF, and PPF, building on Phase 2 data showing a 35.5% reduction in pulmonary vascular resistance.
Nov 18, 2025, 8:30 AM
Insmed Discusses Strong Brensocatib Launch and Future Pipeline Growth
INSM
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Insmed reported a strong early launch for Brensocatib in bronchiectasis, achieving $28 million in revenue in its partial first quarter, with projections for over $5 billion in peak sales in this indication alone.
- The company anticipates key data readouts, including for CRS without nasal polyps by early January 2026, which could unlock a "skeleton key" medicine, and the ARIKAYCE ENCORE trial in the first half of next year, potentially expanding its market opportunity from 30,000 to 250,000 patients.
- Insmed plans to initiate four Phase 3 programs for TPIP in PAH, PH-ILD, IPF, and PPF, with analysts modeling $7 billion in peak sales for TPIP in PAH alone.
- With a robust R&D pipeline and the revenue generation potential of Brensocatib, Insmed is on an "almost inevitable journey to cash flow positivity".
Nov 18, 2025, 8:30 AM
Insmed Highlights Strong Brensocatib Launch, ARIKAYCE Expansion, and TPIP Phase 3 Advancement
INSM
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Insmed's newly approved drug, Brensocatib, for bronchiectasis, generated $28 million in revenue in its initial partial quarter, with management projecting over $5 billion in peak sales for this indication alone.
- The company anticipates significant market expansion for ARIKAYCE with the ENCORE trial readout in the first half of next year, potentially increasing the addressable patient population from 30,000 to 250,000 across the U.S., Europe, and Japan.
- Insmed is advancing TPIP into Phase 3 trials for multiple indications, including PAH, PH-ILD, IPF, and PPF, following Phase 2 data showing a 35.5% reduction in pulmonary vascular resistance in PAH, with some models projecting $7 billion in peak sales for PAH alone.
- Key upcoming catalysts include data readouts for Brensocatib in CRS (by year-end 2025, public in early January 2026), targeting a market of over 30 million patients in the U.S. and potentially exceeding the bronchiectasis opportunity, and the company expects Brensocatib's revenue to drive the company towards cash flow positivity.
Nov 18, 2025, 8:30 AM
Quarterly earnings call transcripts for INSMED.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more